All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-06-05T11:32:00.000Z

ASCO 2019 | Should patients with FLT3-ITD receive allo-HSCT?

By Emily Smith, Michael Heuser
Featured
Michael Heuser
Jun 5, 2019
Share:

Bookmark this article

At the 2019 ASCO Annual Meeting in Chicago, US,  Michael Heuser from Hannover Medical School, Hannover, DE, discusses whether patients with FLT3-ITD should receive allo-HSCT. In Europe, allo-HSCT has been distinguished for the allelic ratio, there are patients that have an allelic ratio of 0.5 and patients that have an allelic ratio of 0.5 or higher.

Should patients with FLT3-ITD receive allo-HSCT?

More about...
Allo-HSCTAML-related mutationsASCO 2019FLT3-ITDNPM1

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 79 days left ...

Related articles

Add bookmark

Application of minimal residual disease testing in assessing response to treatment of AML

At ASCO 2019, Michael Heuser discusses MRD testing and its application to AML patients during treatment and after treatment, to assess the response of patients.

Jun 6, 2019
Add bookmark

Application of minimal residual disease testing in assessing response to treatment of AML

At ASCO 2019, Michael Heuser discusses MRD testing and its application to AML patients during treatment and...

Jun 6, 2019
Add bookmark

ASH 2017 | MRD risk-adapted therapy in AML 

At the 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, the AGP attended an oral session which focused on risk-adapted therapies in Acute Myeloid Leukemia (AML)

Jan 9, 2018
Add bookmark

ASH 2017 | MRD risk-adapted therapy in AML 

At the 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, the AGP attended an oral session which focused on risk-adapted therapies in...

Jan 9, 2018

Newsletter

Subscribe to get the best content related to AML delivered to your inbox